Skip Navigation LinksHome > February 2014 - Volume 63 - Issue 2 > Progress in Gene Therapy for Heart Failure
Journal of Cardiovascular Pharmacology:
doi: 10.1097/FJC.0b013e3182a2e8b8
Invited Review Article

Progress in Gene Therapy for Heart Failure

Yerevanian, Armen MD; Yerevanian, Alexan BS; Hajjar, Roger J. MD

Collapse Box

Abstract

Recent advances in our understanding of the pathophysiology of myocardial dysfunction in the setting of congestive heart failure have created a new opportunity in developing nonpharmacological approaches to treatment. Gene therapy has emerged as a powerful tool in targeting the molecular mechanisms of disease by preventing the ventricular remodeling and improving bioenergetics in heart failure. Refinements in vector technology, including the creation of recombinant adeno-associated viruses, have allowed for safe and efficient gene transfer. These advancements have been coupled with evolving delivery methods that include vascular, pericardial, and direct myocardial approaches. One of the most promising targets, SERCA2a, is currently being used in clinical trials. The recent success of the Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease phase 2 trials using adeno-associated virus 1-SERCA2a in improving outcomes highlights the importance of gene therapy as a future tool in treating congestive heart failure.

Copyright © 2013 by Lippincott Williams & Wilkins

Follow Us!

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.